Entity

Time filter

Source Type

DRESDEN, Germany

Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.1.2-5 | Award Amount: 3.64M | Year: 2008

The symptoms of complex disease like allergy, obesity and cancer depend on the products of multiple interacting genes. High-throughput techniques have implicated hundreds of genes. There are also considerable individual variations. A clinical implication of this may be inadequate treatment response, which is increasingly recognized as a cause of increased suffering and costs. Ideally, physicians should be able to routinely personalize medication based on a few diagnostic markers. Finding such markers is a formidable challenge. We hypothesize that translational clinical studies based on high-throughput genomics, advanced computing and systems biology may help to identify markers for personalized medication in complex diseases. We organize disease-associated genes in networks that are analyzed in a top-down manner. First, modules of interacting genes with distinct biological functions are identified. Then the modules are dissected to find pathways and finally upstream genes with key regulatory functions. We use bioinformatic methods that were recently described by us in Nature Genetics and Nature Biotechnology. An important focus of this project is to develop these methods to form multi-layer modules that integrate information about disease-associated changes on the DNA, RNA and protein levels. Since these levels interact, studies of the different levels can be interactively used to cross-validate the modules. This involves both genetic and experimental studies, but the ultimate test of the modules will be if they can be used for clinical predictions. For example, changes in RNA expression may be caused by a single nucleotide polymorphism (SNP) in a regulatory region. If so, the corresponding protein is tried as a marker to personalize medication. We have chosen hay fever as a model of complex disease because it is common, well-defined and readily examined in clinical and experimental studies. However, the methods may be generally applicable to complex diseases.


Grant
Agency: Cordis | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2011-IAPP | Award Amount: 1.67M | Year: 2012

An urgent need exists for more specific treatment options to target the metabolic changes and the related inflammatory pathways during HF. Targeting microRNAs (miRNAs)-small RNAs implicated in protein regulation- represents a unique possibility to make novel medicines against HF. In view of the central role of inflammatory pathways in the metabolic syndrome, they expect inflammation miRNAs to be excellent targets to treat HF. Three partners will form a focused and natural industry-academy partnership where essential expertise in clinical and experimental miRNA biology, systems biology and drug development is exchanged. The common goal of the partners is to discover novel miRNAs implicated in the cardiac metabolic disease, to develop medicines targeting these miRNAs, and finally test these innovative miRNA medicines in the metabolic risk induced HF. The project team proposes to support 10 experienced and 1 early stage researchers under the current IAPP Programme. Two of the experience researchers will be recruited for the project. All the researchers will undergo intersectorial movement, either from academia to industry or vice versa. The CardiomiR project aims: To identify miRNAs that are implicated in adverse cardiac inflammation and metabolic changes resulting in HF, and treat HF using LNA-antimiR therapeutics targeting these miRNAs. To exchange researchers to be able to productively combine the skills and know-how of antimiR-drug discovery and development, cardiac disease biology as well as systems biology and omics data analysis. To achieve this, a concerted collaborative effort, exchange and training is proposed here between two academic and one industrial partner University Maastricht (UM, partner 1) , University of Lige (ULG, partner 2) and SANTARIS Pharma (SANTARIS, partner 3) This project consists of 3 RTD work package, a secondment/recruitment workpackage and will concentrate on dissemination (IPR-related) and management.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-1 | Award Amount: 5.90M | Year: 2011

The MEHTRICS proposal aims to challenge the current limits of HT cell-based screening by combining HT-RNAi with an emerging new technology for normalizing cultured cell behaviors, namely the growth of cells on adhesive micropatterns. Initial applications of this technology have already demonstrated its potential for enhancing the quality of existing high content analyses by radically reducing the cell populations phenotypic variability, resulting in much lower cell sampling requirements. This approach also promises to open up major new assay development space by broadening the range of analysis strategies that drive the novel cell-based assay designs, whose evolution has otherwise stagnated in recent years. The consortium will carry out several parallel and complementary lines of development to diversify the applicability of the MEHTRICS platform for both academic and industrial uses, ultimately validating the new capabilities through proof of principle screens. Our key objectives are 1) to optimize micropattern geometries and compositions to accommodate extended timelines typical of siRNA assays, 2) to integrate the promising Transfected Cell Array (TCA) technique to decrease cost and increase throughput, 3) to develop novel cell models of key diseases based on micropatterned adult stem cells and polarized epithelia/endothelial architectures and 4) to validate each of these implementations in key industry-relevant siRNA screening applications. Since experimental designs required to run RNAi screens are among the most demanding of all HT/HC studies and encompass virtually all technical challenges also encountered in compound screens, we expect the proposed scope of activities to deliver the maximal potential for impactful innovation, widespread adoption and clear relevance for all major applications of HT/HC cell screening. The resulting new tools and methodologies will be incorporated into the commercial offerings of the consortiums two key SMEs, CYTOO and CENIX.


Trademark
Cenix Bioscience Gmbh | Date: 2005-11-15

DOWNLOADABLE COMPUTER DATABASES AND COMPUTER DATABASES RECORDED ON COMPUTER MEDIA IN THE FIELDS OF BIOTECHNOLOGY, BIOSCIENCE, GENOMICS, THERAPEUTICS AND PHARMACOLOGY, INCLUDING GENE-SPECIFIC CHARACTERISTICS. PROVIDING MULTIPLE USER ACCESS TO DATABASES IN THE FIELDS OF BIOTECHNOLOGY, BIOSCIENCE, GENOMICS, THERAPEUTICS AND PHARMACOLOGY, INCLUDING GENE-SPECIFIC PHENOTYPE CHARACTERISTICS, ON A GLOBAL COMPUTER INFORMATION NETWORK. scientific, medical and pharmaceutical research and development, namely, the identification, validation and characterization of drug target genes, molecules and biochemical pathways, analysis of gene functions, drug development programs for conventional and RNAi-based therapeutics, screening for pharmacological and biochemical compounds; consulting services in the field of scientific, medical and pharmaceutical research and development; developing and maintaining databases of information for others in the fields of biotechnology, bioscience, genomics, therapeutics, and pharmacology, including gene-specific phenotype characteristics; information services, namely, online databases provided through global communications networks [ and local computer networks ] featuring technological information and scientific and medical research information in the fields of biotechnology, bioscience, genomics, therapeutics and pharmacology. INFORMATION SERVICES, NAMELY, ONLINE DATABASES PROVIDED THROUGH GLOBAL COMMUNICATIONS NETWORKS, [ AND LOCAL COMPUTER NETWORKS ] FEATURING MEDICAL INFORMATION IN THE FIELDS OF BIOTECHNOLOGY, BIOSCIENCE, GENOMICS, THERAPEUTICS AND PHARMACOLOGY.


Trademark
Cenix Bioscience Gmbh | Date: 2005-11-15

downloadable computer databases and computer databases recorded on computer media in the fields of biotechnology, bioscience, genomics, therapeutics and pharmacology, including gene-specific characteristics. providing multiple user access to databases in the fields of biotechnology, bioscience, genomics, therapeutics and pharmacology, including gene-specific phenotype characteristics, on a global computer information network. scientific, medical and pharmaceutical research and development, namely, the identification, validation and characterization of drug target genes, molecules and biochemical pathways, analysis of gene functions, drug development programs for conventional and RNAi-based therapeutics, screening for pharmacological and biochemical compounds; consulting services in the field of scientific, medical and pharmaceutical research and development; developing and maintaining databases of information for others in the fields of biotechnology, bioscience, genomics, therapeutics, and pharmacology, including gene-specific phenotype characteristics; information services, namely, online databases provided through global communications networks [ and local computer networks ] featuring technological information and scientific and medical research information in the fields of biotechnology, bioscience, genomics, therapeutics and pharmacology. information services, namely, online databases provided through global communications networks [, and local computer networks ] featuring medical information in the fields of biotechnology, bioscience, genomics, therapeutics and pharmacology.

Discover hidden collaborations